Disruption of endolysosomal Rab5/7 efficiently eliminates colorectal cancer stem cells

Mitsunobu Takeda, Jun Koseki, Hidekazu Takahashi, Norikatsu Miyoshi, Naohiro Nishida, Junichi Nishimura, Taishi Hata, Chu Matsuda, Tsunekazu Mizushima, Hirofumi Yamamoto, Hideshi Ishii, Yuichiro Doki, Masaki Mori, Naotsugu Haraguchi

研究成果: ジャーナルへの寄稿記事

抄録

Given that cancer stem cells (CSC) play a key role in drug resistance and relapse, targeting CSCs remains promising in cancer therapy. Here we show that RAB5/7, which are involved in the endolysosomal pathway, play key roles in the maintenance of CSC survival via regulation of the mitophagic pathway. Inhibition of RAB5/7 efficiently eliminated colorectal CSCs and disrupted cancer foci. In addition, we identified mefloquine hydrochloride, an antimalarial drug, as a novel RAB5/7 inhibitor and promising colorectal CSC-targeting drug. Endolysosomal RAB5/7 and LAMP1/2 mediated parkin-dependent mitochondrial clearance and modulated mitophagy through lysosomal dynamics. In a patient-derived xenograft (PDX) model of colon cancer, treatment with mefloquine resulted in suppression of mitophagic PINK1/PARKIN and increased mitochondrial disorder and mitochondria-induced apoptosis without apparent side effects. These results suggest that the combination of mefloquine with chemotherapeutic agents in the PDX model potentially disrupts the hierarchy of colorectal cancer cells and identify endolysosomal RAB5/7 and LAMP1/2 as promising therapeutic targets in CSCs. Significance: These findings show that endosomal/lysosomal RAB5 and RAB7, which regulate mitophagy, are essential for the survival of colon cancer stem cells.

元の言語英語
ページ(範囲)1426-1437
ページ数12
ジャーナルCancer Research
79
発行部数7
DOI
出版物ステータス出版済み - 1 1 2019
外部発表Yes

Fingerprint

Neoplastic Stem Cells
Mefloquine
Colorectal Neoplasms
Mitochondrial Degradation
Heterografts
Colonic Neoplasms
Mitochondrial Diseases
Antimalarials
Proxy
Drug Delivery Systems
Drug Resistance
Neoplasms
Cell Survival
Mitochondria
Therapeutics
Maintenance
Apoptosis
Recurrence
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Takeda, M., Koseki, J., Takahashi, H., Miyoshi, N., Nishida, N., Nishimura, J., ... Haraguchi, N. (2019). Disruption of endolysosomal Rab5/7 efficiently eliminates colorectal cancer stem cells. Cancer Research, 79(7), 1426-1437. https://doi.org/10.1158/0008-5472.CAN-18-2192

Disruption of endolysosomal Rab5/7 efficiently eliminates colorectal cancer stem cells. / Takeda, Mitsunobu; Koseki, Jun; Takahashi, Hidekazu; Miyoshi, Norikatsu; Nishida, Naohiro; Nishimura, Junichi; Hata, Taishi; Matsuda, Chu; Mizushima, Tsunekazu; Yamamoto, Hirofumi; Ishii, Hideshi; Doki, Yuichiro; Mori, Masaki; Haraguchi, Naotsugu.

:: Cancer Research, 巻 79, 番号 7, 01.01.2019, p. 1426-1437.

研究成果: ジャーナルへの寄稿記事

Takeda, M, Koseki, J, Takahashi, H, Miyoshi, N, Nishida, N, Nishimura, J, Hata, T, Matsuda, C, Mizushima, T, Yamamoto, H, Ishii, H, Doki, Y, Mori, M & Haraguchi, N 2019, 'Disruption of endolysosomal Rab5/7 efficiently eliminates colorectal cancer stem cells' Cancer Research, 巻. 79, 番号 7, pp. 1426-1437. https://doi.org/10.1158/0008-5472.CAN-18-2192
Takeda M, Koseki J, Takahashi H, Miyoshi N, Nishida N, Nishimura J その他. Disruption of endolysosomal Rab5/7 efficiently eliminates colorectal cancer stem cells. Cancer Research. 2019 1 1;79(7):1426-1437. https://doi.org/10.1158/0008-5472.CAN-18-2192
Takeda, Mitsunobu ; Koseki, Jun ; Takahashi, Hidekazu ; Miyoshi, Norikatsu ; Nishida, Naohiro ; Nishimura, Junichi ; Hata, Taishi ; Matsuda, Chu ; Mizushima, Tsunekazu ; Yamamoto, Hirofumi ; Ishii, Hideshi ; Doki, Yuichiro ; Mori, Masaki ; Haraguchi, Naotsugu. / Disruption of endolysosomal Rab5/7 efficiently eliminates colorectal cancer stem cells. :: Cancer Research. 2019 ; 巻 79, 番号 7. pp. 1426-1437.
@article{c722de620dae4ea8b070a9a886e77508,
title = "Disruption of endolysosomal Rab5/7 efficiently eliminates colorectal cancer stem cells",
abstract = "Given that cancer stem cells (CSC) play a key role in drug resistance and relapse, targeting CSCs remains promising in cancer therapy. Here we show that RAB5/7, which are involved in the endolysosomal pathway, play key roles in the maintenance of CSC survival via regulation of the mitophagic pathway. Inhibition of RAB5/7 efficiently eliminated colorectal CSCs and disrupted cancer foci. In addition, we identified mefloquine hydrochloride, an antimalarial drug, as a novel RAB5/7 inhibitor and promising colorectal CSC-targeting drug. Endolysosomal RAB5/7 and LAMP1/2 mediated parkin-dependent mitochondrial clearance and modulated mitophagy through lysosomal dynamics. In a patient-derived xenograft (PDX) model of colon cancer, treatment with mefloquine resulted in suppression of mitophagic PINK1/PARKIN and increased mitochondrial disorder and mitochondria-induced apoptosis without apparent side effects. These results suggest that the combination of mefloquine with chemotherapeutic agents in the PDX model potentially disrupts the hierarchy of colorectal cancer cells and identify endolysosomal RAB5/7 and LAMP1/2 as promising therapeutic targets in CSCs. Significance: These findings show that endosomal/lysosomal RAB5 and RAB7, which regulate mitophagy, are essential for the survival of colon cancer stem cells.",
author = "Mitsunobu Takeda and Jun Koseki and Hidekazu Takahashi and Norikatsu Miyoshi and Naohiro Nishida and Junichi Nishimura and Taishi Hata and Chu Matsuda and Tsunekazu Mizushima and Hirofumi Yamamoto and Hideshi Ishii and Yuichiro Doki and Masaki Mori and Naotsugu Haraguchi",
year = "2019",
month = "1",
day = "1",
doi = "10.1158/0008-5472.CAN-18-2192",
language = "English",
volume = "79",
pages = "1426--1437",
journal = "Cancer Research",
issn = "0008-5472",
number = "7",

}

TY - JOUR

T1 - Disruption of endolysosomal Rab5/7 efficiently eliminates colorectal cancer stem cells

AU - Takeda, Mitsunobu

AU - Koseki, Jun

AU - Takahashi, Hidekazu

AU - Miyoshi, Norikatsu

AU - Nishida, Naohiro

AU - Nishimura, Junichi

AU - Hata, Taishi

AU - Matsuda, Chu

AU - Mizushima, Tsunekazu

AU - Yamamoto, Hirofumi

AU - Ishii, Hideshi

AU - Doki, Yuichiro

AU - Mori, Masaki

AU - Haraguchi, Naotsugu

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Given that cancer stem cells (CSC) play a key role in drug resistance and relapse, targeting CSCs remains promising in cancer therapy. Here we show that RAB5/7, which are involved in the endolysosomal pathway, play key roles in the maintenance of CSC survival via regulation of the mitophagic pathway. Inhibition of RAB5/7 efficiently eliminated colorectal CSCs and disrupted cancer foci. In addition, we identified mefloquine hydrochloride, an antimalarial drug, as a novel RAB5/7 inhibitor and promising colorectal CSC-targeting drug. Endolysosomal RAB5/7 and LAMP1/2 mediated parkin-dependent mitochondrial clearance and modulated mitophagy through lysosomal dynamics. In a patient-derived xenograft (PDX) model of colon cancer, treatment with mefloquine resulted in suppression of mitophagic PINK1/PARKIN and increased mitochondrial disorder and mitochondria-induced apoptosis without apparent side effects. These results suggest that the combination of mefloquine with chemotherapeutic agents in the PDX model potentially disrupts the hierarchy of colorectal cancer cells and identify endolysosomal RAB5/7 and LAMP1/2 as promising therapeutic targets in CSCs. Significance: These findings show that endosomal/lysosomal RAB5 and RAB7, which regulate mitophagy, are essential for the survival of colon cancer stem cells.

AB - Given that cancer stem cells (CSC) play a key role in drug resistance and relapse, targeting CSCs remains promising in cancer therapy. Here we show that RAB5/7, which are involved in the endolysosomal pathway, play key roles in the maintenance of CSC survival via regulation of the mitophagic pathway. Inhibition of RAB5/7 efficiently eliminated colorectal CSCs and disrupted cancer foci. In addition, we identified mefloquine hydrochloride, an antimalarial drug, as a novel RAB5/7 inhibitor and promising colorectal CSC-targeting drug. Endolysosomal RAB5/7 and LAMP1/2 mediated parkin-dependent mitochondrial clearance and modulated mitophagy through lysosomal dynamics. In a patient-derived xenograft (PDX) model of colon cancer, treatment with mefloquine resulted in suppression of mitophagic PINK1/PARKIN and increased mitochondrial disorder and mitochondria-induced apoptosis without apparent side effects. These results suggest that the combination of mefloquine with chemotherapeutic agents in the PDX model potentially disrupts the hierarchy of colorectal cancer cells and identify endolysosomal RAB5/7 and LAMP1/2 as promising therapeutic targets in CSCs. Significance: These findings show that endosomal/lysosomal RAB5 and RAB7, which regulate mitophagy, are essential for the survival of colon cancer stem cells.

UR - http://www.scopus.com/inward/record.url?scp=85064142867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064142867&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-18-2192

DO - 10.1158/0008-5472.CAN-18-2192

M3 - Article

VL - 79

SP - 1426

EP - 1437

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 7

ER -